Search

Tapinarof

It is available as a topical cream to be applied to the affected area once daily. … [A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]

D-Levofloxacin

A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Edotecarin

Edotecarin is a novel, non-camptothecin, DNA topoisomerase I inhibitor. It is member of the class of compounds called indolocarbazoles.

Crypthecodinium cohnii DHA oil

Alglucerase

Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.

Apremilast

[L7501] In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and … Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases.

Ferric sulfate

[A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003] … Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with acidic properties. It is produced by the reaction of sulfuric acid and an oxidizing agent.

Lifitegrast

Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). … It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process.

Brensocatib

[A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation. … [A274348,A274343] It reduces exacerbations and slows lung function decline, offering a targeted approach to managing NCFB.

Magnesium silicate

[L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605] … Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water.